PA-PMI
12.9.2019 15:02:08 CEST | Business Wire | Press release
Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI @ Work: New Projects, New Thinking. The report, a companion piece to AI Innovators: Cracking the Code on Project Performance , explores how artificial intelligence (AI) is changing the way projects are managed and delivered globally.
As AI projects become the norm, project managers need to better understand what technologies will help them streamline and improve their AI-based project work -- or they risk being left behind. The new report highlights the top AI technologies project leaders are currently leveraging to boost project management productivity, and how to incorporate AI technologies into their overall project work.
While project leaders are tapping into AI technologies to boost project productivity and quality, unlocking AI’s full potential requires building and constantly refreshing knowledge of emerging technologies. In fact, the report finds that organizations and their project leaders will need a high Project Management Technology Quotient (PMTQ) – a way of evaluating an organization’s ability to manage and integrate technology based on the needs of the organization or the project at hand – to turn AI strategy into reality.
“In today’s increasingly project-based economy, the most forward-thinking organizations know that the success of their strategies hinges on how well they can execute projects. And the race toward AI mastery is no exception,” said Michael DePrisco, vice president of global solutions at PMI. “As we see AI technologies continue to be integrated into organizations, the research indicates that project managers, especially those with a high PMTQ, are well prepared to play an integral role in implementation.”
Of the respondents to the study, 50 percent reported a high PMTQ (Innovators) and 10 percent reported only sometimes or never practicing the principles of the PMTQ (Laggards).
A majority of both groups say their project management skills and experience are a good foundation for managing AI. But the Innovators have the upper hand: 74 percent of Innovators say they’re confident their current skill set enables them to work with AI, compared with 51 percent of Laggards.
Even more so, Innovators cite having more awareness and experience with several AI technologies, including knowledge-based systems, decision management, speech recognition, and expert systems. These respondents also report delivering better outcomes when using AI technologies, including a decreased amount of time spent on activities like monitoring progress, managing documentation, as well as activity and resource planning.
The top technologies respondents cite as enhancing productivity are:
- Robotic process automation: Technology that mimics and automates human tasks to support corporate processes.
- Machine learning: Technology that allows computers to learn by employing pattern detection for improved decisions in subsequent situations.
- Reinforcement learning: A machine learning technique that enables software to learn in an interactive environment by trial and error using feedback from its own actions.
The top technologies respondents identify as increasing quality are:
- Anti-bias solutions: Technology that automatically identifies bias in a range of AI algorithms.
- Expert systems: Technology that emulates and mimics human intelligence, skills or behavior and usually offers expert knowledge in a particular field, topic, or skill.
- Knowledge-based systems: Technology that understands the context of the data being processed to help problem-solve procedures and support human learning, decision making, and actions.
While it is clear AI can make a difference in value delivery, it is up to organizations and their project leaders to identify and understand which technologies can best help them achieve their specific goals and deliver long-term success.
Read more about 2019 Pulse of the Profession® In-Depth Report: AI Innovators: AI @ Work: New Projects, New Thinking. The Pulse of the Profession® In-Depth research was conducted online in June/July 2019 among 780 project management practitioners globally.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Founded in 1969, PMI delivers value for more than three million professionals working in nearly every country in the world through global advocacy, collaboration, education and research. We advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005049/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
